Summary
- Happy HD Awareness Month!
- Neurocrine Biosciences announces approval of new formulation of INGREZZA
- Upcoming Research Webinar: Drugs and Trials for Huntington’s Disease
Happy HD Awareness Month!
May is Huntington’s Disease Awareness Month, and we need your help to turn up the volume on HD awareness! #LetsTalkAboutHD is a social media initiative during Huntington’s Disease Awareness Month in May to encourage families to share their experiences with HD. It can be a video, a photo or a written story – HD impacts every family differently and it’s time the world knows our story. All stories are welcome – research included! Together we can spread awareness about Huntington’s disease. Learn more here.
Neurocrine Biosciences announces approval of new formulation of INGREZZA
Last year, the FDA approved the drug valbenazine, also known as INGREZZA, to treat chorea in people with HD. Earlier this week, Neurocrine Biosciences announced approval of INGREZZA SPRINKLE capsules. While the drug remains the same, this new granular formulation of valbenazine can be easily added to soft foods and may be more accessible for individuals who have difficulty swallowing pills. Read more in the press release from Neurocrine, here.
Upcoming Research Webinar: Drugs and Trials for Huntington’s Disease
Join the Hereditary Disease Foundation on Tuesday, May 14th, at 12 PM ET for the next installment of their research webinar series, “Drugs and Trials for Huntington’s Disease: The Good, The Bad, and The Future,” featuring Drs. Frank Bennett and Ed Wild. Register to join here. To learn more about the speakers or view previous HDF Research webinars, visit their website here.
